Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics

Pharmaceutical Executive Daily: Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics

Published 3 months ago
Description
Mereo BioPharma licenses its lung disease treatment alvelestat to Sentynl Therapeutics, Krieger Scientific's Joseph Morwald examines what's driving a surge in FDA warning letters, and IQVIA's Christopher Wooden and Tom Woods make the case for persona-based HCP engagement.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us